biotech.today

Details

  • ●Modalities: mRNA vaccines, mRNA therapeutics, personalized cancer vaccines
  • ●Therapeutic areas: infectious diseases, oncology, rare diseases, autoimmune, cardiovascular
  • ●Key targets: SARS-CoV-2, RSV, influenza, patient-specific neoantigens, KRAS
  • ●Indications: COVID-19, RSV, influenza, melanoma (personalized cancer vaccine)
  • ●Funding: N/A (public since 2018, ~$36B COVID vaccine revenue 2021-2023)

Partners & investors

  • Public (NASDAQ: MRNA)· Investor

Key considerations

  • ●AI tools in use: OpenAI partnership (enterprise-wide), Proprietary mRNA design engine, AI-driven manufacturing optimization
  • ●Strategic partnership with OpenAI for AI-powered mRNA medicine development
  • ●750+ custom GPTs deployed across the organization
  • ●AI used for mRNA sequence optimization, clinical trial design, and manufacturing

Pipeline

  • Phase 32
  • Approved2
Get live updates on Moderna’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Stéphane Bancel

CEO

mRNA technologybiotech leadershipmanufacturing scale-up

Stephen Hoge

President

mRNA therapeuticsclinical developmentplatform science
Visit website →LinkedIn →